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Disruption to lung smooth muscle development and function in
humans can lead to chronic health complications including asthma
and pulmonary hypertension (Camoretti-Mercado et al., 2003;
Halayko et al., 1998; Halayko and Stephens, 1994; Humbert et al.,
2004; Solway et al., 1998). Understanding the signaling pathways
coordinating the various speciﬁcation and differentiation processes
occurring during smooth muscle development are critical to a
complete understanding of lung development as well as pathogenesis
in the postnatal lung. In the early lung bud, the condensing lung
mesenchyme is thought to generate several cell lineages including
smoothmuscle cells, endothelial cells, and resident ﬁbroblasts such as
myoﬁbroblasts, lipoﬁbroblasts, and stromal ﬁbroblasts (reviewed in
Morrisey and Hogan(2010). At the level of the mainstem bronchi,
smooth muscle develops partially around the airway on the dorsal
surface with cartilaginous rings forming on the ventral surface.
Slightly more posterior in the proximal airways, smoothmuscle forms
around the entire epithelium while the most distal portion of the
respiratory tree lacks smooth muscle (Tollet et al., 2001, 2002).
Airway smooth muscle development (ASM) closely follows thegrowth and differentiation of the airway epithelium temporally and
spatially. At E11.5 in the mouse, a smooth muscle layer starts to
envelop the trachea and proximal bronchi and continues to develop
around the proximal airway tubules as lung development progresses
(Badri et al., 2008). Current theories suggest that ASM originates from
a distal pool of Fgf10-expressing mesenchymal cells that surrounds
the tip of the branching airway epithelium (Mailleux et al., 2005;
Ramasamy et al., 2007). These distal cells proliferate and actively or
passively translocate to surround the proximal airways undergoing
epithelial tube outgrowth and branching.
Several signaling pathways are known to be critical in lung smooth
muscle development including FGF, BMP, Shh, and Wnt signaling.
Fgf10 signaling is important for ASM development and mediates this
process in part, through signaling interactions with the epithelium.
Fgf10 signaling from the mesenchyme activates a gene expression
program in the adjacent developing epithelium, which signals in a
reciprocal fashion back to the mesenchyme to direct smooth muscle
differentiation (Mailleux et al., 2005). The pro-myogenic signals
expressed in the developing airway epithelium include Shh and Bmp4
and these factors direct smooth muscle differentiation along the
branching epithelial tubule as Fgf10-expressing cells condense around
the primitive airway (Mailleux et al., 2005). Fgf9 signaling from the
mesothelium is also reported to mediate the development of
immature smooth muscle cells in the distal mesenchyme by limiting
the differentiation response of the mesenchyme to Shh signaling
(Colvin et al., 2001).
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543A.M. Goss et al. / Developmental Biology 356 (2011) 541–552Published data indicate that Wnt/β-catenin signaling is active and
plays a role during smoothmuscle development in the lung. FromE14.5
to E18.5,Wnt/β-catenin signaling activity is observed in the developing
ASM(Shuet al., 2005).Wnt7b is a canonicalWnt ligand expressed in the
developing epithelium, and Wnt7b knockout mice display perinatal
pulmonary hemorrhaging due to disrupted vascular smooth muscle
(VSM) development (Shu et al., 2002). Further investigation into the
mechanisms ofWnt7b signaling revealed thatWnt7b broadly regulates
the development of smooth muscle cells in the early lung bud
mesenchyme (Cohen et al., 2009). Additionally, treating lung explants
with the canonical Wnt signaling inhibitor Dickkopf-1 (Dkk-1) impairs
smooth muscle gene expression (De Langhe et al., 2005).
Wnt2 is a ligand robustly expressed throughout the lung mesen-
chymeduring the course of lung development.Wnt2 isﬁrst expressed in
themesoderm surrounding the anterior foregut endoderm from E9.0 to
E9.5 during theperiodwhen the lung is speciﬁed, andWnt2 continues to
be expressed in the mesoderm condensing around the early lung bud
to form the primitive lung mesenchyme with expression persisting up
to perinatal timepoints (Goss et al., 2009; Monkley et al., 1996). The
expression pattern of Wnt2 suggests that it may play a role in the
development of mesenchymal-derived lineages in the lung. Previous
work has shown that Wnt2, in cooperation withWnt2b, is essential for
speciﬁcation of the respiratory lineage in the anterior foregut endoderm
(Goss et al., 2009). However, whether Wnt2 plays a role in regulating
mesenchymal lineage differentiation in the lung is unclear. In this
report, we show that a loss of Wnt2 leads to a severe deﬁciency in ASM
development in the lung. We show that Wnt2 acts upstream of Fgf10
and the critical transcription factors myocardin and Mrtf-B to regulate
early ASM differentiation in the multipotent lung mesenchyme.
Moreover, Wnt2 acts in a paracrine manner to promote Wnt7b
expression in the endoderm which in turn promotes lung smooth
muscle development. Thus, Wnt2 plays an important role in the lung
mesenchyme by promoting the earliest stages of ASM development in
addition to its role in specifying the respiratory endoderm fate.
2. Results
2.1. Wnt2−/− null lungs exhibit airway smooth muscle defects
Wnt2 is robustly expressed in the developing lung mesenchyme
throughout lung development (Goss et al., 2009). To investigate
whether Wnt2 regulates mesenchymal development, E18.5 wild type
control and Wnt2−/− null mutant embryos were examined for
smooth muscle defects. Immunostaining for SM22α expression, a
marker of smoothmuscle cells, revealed a reduction in smoothmuscle
surrounding the proximal and distal bronchiolar airways (Fig. 1A andB
and data not shown). Higher magniﬁcation of Wnt2−/− null mutant
lung cross-sections showed sporadic SM22α-expressing cells around
the airways, resulting in signiﬁcant gaps in the sub-epithelial ASM
layer (Fig. 1C and D). Interestingly, SM22α expression in the smooth
muscle layer of adjacent pulmonary arteries appeared unchanged
(Fig. 1A and B, arrows).
2.2. Wnt2 signaling through β-catenin regulates airway smooth muscle
development in the lung mesenchyme
TheWnt/β-catenin transgenic reporter mice BAT-GAL and TOP-GAL
reveal Wnt/β-catenin signaling activity in the developing lungFig. 1.Wnt2−/− lungs exhibit airway smooth muscle (ASM) defects. SM22α immunostainin
(B, D) demonstrates reduced ASM in the distal airways ofWnt2−/− null lungs. Higher magn
distal airway epithelium inWnt2−/− null lungs (D, arrowheads). The smooth muscle layer su
sections of lacZ-stained E14.5 control BAT-GAL embryos shows lacZ expression in the develo
GALmutant embryos there is decreased lacZ expression in primitive ASM cells (F, arrowhead
on E14.5 control wild type lung cross-sections demonstrates robust expression in the develo
arrowhead). Q-PCR of Axin2 expression demonstrates a signiﬁcant reduction in E14.5Wnt2−
buds. Airways denoted by (*) symbol on histological sections. Scale bars=200 μm (A, B, E,smooth muscle (Okubo and Hogan, 2004; Shu et al., 2005), and
Wnt2 is reported to signal canonically through the Wnt/β-catenin
pathway in the lung (Goss et al., 2009). To determine if Wnt2 is
required for Wnt/β-catenin signaling activity in the developing ASM,
Wnt2+/− mutants were crossed into the transgenic BAT-GAL reporter
background to yield Wnt2−/−:BAT-GAL embryos (Fig. 1E and F). In
E14.5 control BAT-GAL embryos, lacZ-positive cells were labeled in the
developing epithelium and in the presumptive ASM layer (Fig. 1E). In
Wnt2−/−:BAT-GAL mutants, there was a reduction in the number of
lacZ-positive cells in the developing ASM layer, indicating a loss of
Wnt/β-catenin activity in these cells (Fig. 1F). BAT-GAL activity was
also reduced in Wnt2−/−:BAT-GAL mutant lung epithelium as
previously reported (Fig. 1F and (Goss et al., 2009). Additionally,
immunostaining for Axin2, a Wnt/β-catenin transcriptional target
(Jho et al., 2002), showed reduced expression in the presumptive ASM
layer of E14.5 Wnt2−/− null lungs (Fig. 1G and H). Quantiﬁcation of
Axin2 gene expression in E14.5 control and Wnt2−/− null lungs
conﬁrmed a signiﬁcant reduction in the level of Axin2 expression in
the absence ofWnt2 signaling (Fig. 1I). Together, thesedata suggest that
Wnt2 signals through the β-catenin dependent canonical pathway in
the lung mesenchyme to mediate proper ASM development.
2.3. Wnt2 regulates development of immature smooth muscle from the
lung mesenchyme
We hypothesized that the loss of mature ASM in Wnt2−/− null
mutants was due to an early loss of SMC development in the primitive
mesenchyme. SM22α is a marker of both primitive and mature SMCs
(Solway et al., 1995). In E11.5 wild type embryos, SM22α expression
was observed in a sub-epithelial population of cells forming around
the developing proximal airway (Fig. 2A). In Wnt2−/− null embryos,
this expression was reduced indicating a loss of SMC differentiation in
the absence of Wnt2 signaling (Fig. 2B). Quantitative PCR (Q-PCR) on
E11.5 control andWnt2−/− null lung buds conﬁrmed an approximate
50% reduction of SM22α expression in Wnt2−/− null lung buds
(Fig. 2I). At E14.5, a thick and contiguous layer of SM22α-expressing
cells was observed in the developing ASM of wild type embryos
(Fig. 2C). In contrast, fewer SM22α expressing cells were labeled in
Wnt2−/− null lungs and the loss results in a thinned layer of ASMwith
pronounced gaps along the epithelium-mesenchyme border (Fig. 2D).
Pdgfrα and Pdgfrβ are receptor tyrosine kinases through which
members of the platelet-derived growth factor family (Pdgf) of
ligands signal to regulate proliferation, migration, and differentiation
of embryonic mesenchyme (reviewed in (Betsholtz, 2004). Pdgfrα
and Pdgfrβ are broadly expressed in the multipotent mesenchymal
cells of the early lung bud and are important in the development of
smoothmuscle cells from the lungmesenchyme (Bostrom et al., 1996;
Hellstrom et al., 1999). Both receptors continue to be expressed in the
embryonic lung in both ASM and VSM (Cohen et al., 2009).
In E11.5 wild type embryos, expression of Pdgfrβ was observed in
mesenchymal cells that are coalescing around the developing airways
and vasculature (Fig. 2E). However, inWnt2−/− null embryos, Pdgfrβ
expression was reduced throughout the mesenchyme (Fig. 2F). Q-PCR
on E11.5 control and Wnt2−/− null lung buds demonstrated a
signiﬁcant reduction in Pdgfrβ expression (Fig. 2I). In E14.5 wild
type embryos, Pdgfrβ expression was observed in the sub-epithelial
mesenchyme as well as the developing smooth muscle encompassing
the vasculature (Fig. 2G, arrowhead). InWnt2−/−null embryos, Pdgfrβg on cross-sections of E18.5 control wild type (A, C) andWnt2−/− null mutant embryos
iﬁcation (C, D) reveals the lack of a contiguous layer of smooth muscle surrounding the
rrounding adjacent blood vessels does not appear to be affected (arrows in A, B). Cross-
ping epithelium (E, arrows) and primitive ASM cells (E, arrowheads). InWnt2−/−:BAT-
), while some epithelial lacZ expression is retained (F, arrows). Axin2 immunostaining
ping ASM (G, arrowhead), and this expression is reduced inWnt2−/−mutant lungs (H,
/− lungs compared to control wild type lungs (I). *pb0.02 (Student's t test). N=5 lung
F), 100 μm (C, D, G, H).
544 A.M. Goss et al. / Developmental Biology 356 (2011) 541–552expression in the mesenchyme surrounding the airways was reduced
whereas Pdgfrβ expression in the VSM did not appear to be effected
(Fig. 2H, arrowhead). At E14.5 Pdgfrα was also found to be robustlySM
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Fig. 3.Wnt2 signaling is upstream of an early smooth muscle regulatory network. In situ hybridizations formyocardin expression on control wild type lung cross-sections (A and C)
show expression in the primitive smoothmuscle layer surrounding the developing airways at E11.5 (A, arrowheads) and later at E14.5 (C, arrowheads). In comparison,Wnt2−/− null
lungs (B and D) show reducedmyocardin expression in the primitive ASM layer at E11.5 (B, arrowhead) and E14.5 (D, arrowheads). Assessment of smooth muscle regulatory genes
by Q-PCR demonstrates signiﬁcantly reduced levels of myocardin andMrtf-B expression in E11.5Wnt2−/− null lung buds compared to control lung buds (E). *, pb0.02, (Student's t
test). N=5 lung buds. Lung bud circumscribed with dashed line in panels A and B. Airways denoted by (*) symbol on histological sections. Scale bars=400 μm.
545A.M. Goss et al. / Developmental Biology 356 (2011) 541–552this data suggests that loss of Wnt2 function disrupts the development
of a SM22α+;Pdgfrα/β+population of immature SMCs in the early lung
mesenchyme, which leads to a loss of mature ASM.
2.4. Wnt2 signaling is necessary for activation of the smooth muscle
transcription factors myocardin and Mrtf-B in the lung
To assess whether the earliest stages of smooth muscle cell
differentiation are activated in Wnt2−/− null lungs, expression levels
of the transcription factors myocardin and Mrtf-B were examined.
Myocardin and Mrtf-B are members of the myocardin related
transcription factor (Mrtf) family of serum response factor (SRF) co-
factors and expressed in the developing andmature smoothmuscle of
several tissues including the lung (reviewed in (Wang and Olson,
2004). Myocardin is a critical upstream regulator of myogenesis and
in primitive smooth muscle cells, myocardin transactivates numerous
smooth muscle differentiation genes including SM22α and smooth
muscle α-actin (SMA) (Wang et al., 2001; Wang et al., 2003). At E11.5,
in situ hybridizations on wild type embryos showed myocardin
expression around the proximal airway of the primary lung bud
(Fig. 3A, arrowheads). In Wnt2-/− null mutant embryos at both E11.5
and E14.5, there was a reduction inmyocardin expression surrounding
the developing airway (Fig. 3A–D). Quantiﬁcation of myocardin
expression levels in E11.5 control and Wnt2−/− null lung buds
demonstrated an approximate 80% reduction inmyocardin expression
in Wnt2−/− null lung buds (Fig. 3E). Additionally, quantiﬁcation of
Mrtf-B expression was also signiﬁcantly reduced in E11.5 Wnt2−/−
null lung buds as compared to control lung buds (Fig. 3E). The loss of
myocardin andMrtf-B expression inWnt2−/− null lung buds indicates
the down-regulation of an early myogenic transcriptional program inFig. 2. Loss ofWnt2 disrupts development of the lung mesenchyme and immature smooth m
embryos shows expression in the primitive ASM layer surrounding the developing epitheliu
epithelial smooth muscle layer (C, arrowhead). In contrast,Wnt2−/− null mutant lungs exhi
this expression remains reduced at E14.5 (D, arrowheads). Pdgfrβ immunostaining on wild t
the primitive airways and vessels (v) at E11.5 (E) and E14.5 (G). InWnt2−/− null lungs Pdgf
airways. However, Pdgfrβ expression is retained in the mesenchyme condensing around pr
Pdgfrβ expression in E11.5 Wnt2−/− lungs compared to control wild type lungs (I). *,pb0
histological sections. Scale bars=200 μm.the lung, suggesting that Wnt2 is required for initiation of the smooth
muscle gene program in the developing lung.
2.5. Differentiation of other mesenchymal-derived lineages in Wnt2−/−
null lungs
Multiple cell types are hypothesized to derive from the developing
lung mesenchyme including endothelial and lymphatic cell lineages
(Chinoy, 2003). Moreover, lung mesenchyme could provide a
necessary source of signaling factors, including Wnt2, required for
proper investment of vascular endothelium from outside the lung.
Thus, we sought to determine whether differentiation of other
mesenchymal lineages including vascular and lymphatic endothelial
cell lineages were affected in Wnt2−/− mutants.
Q-PCR was performed on E12.5 control and Wnt2−/− null lung
buds to assess endothelial marker gene expression. Pecam1 expres-
sion was not signiﬁcantly reduced inWnt2−/− null lung buds whereas
Flk1 was slightly reduced to 85% of wild type expression (Fig. 4A
and B). Immunostaining conﬁrmed that PECAM1 (CD31) expression
was unaltered in Wnt2−/− mutants (Supplemental Fig. 2). Members
of the Vegf family of molecules are important for regulating vascular
and lymphatic development in multiple tissue types (Lohela et al.,
2009). Vegf-A, Vegf-C, and Vegf-D are expressed in the lung during
development and Vegf-A and Vegf-D are critical for proper vascular
endothelial development while Vegf-C is necessary for lymphatic
endothelial development (Karkkainen et al., 2004; Thebaud, 2007). Q-
PCR revealed comparable expression levels of Vegf-A and Vegf-D
between control and Wnt2−/− null lung buds (Fig. 4C and D).
Interestingly, Vegf-C expression was signiﬁcantly reduced inWnt2−/−
null lung buds (Fig. 4E). Vegf-C signals predominantly through Vegfr-uscle. SM22α immunostaining (A–D) on cross-sections of control wild type (A and C)
m at E11.5 (A, arrowhead) and by E14.5 there is robust SM22α expression in the sub-
bit reduced SM22α expression in the primitive ASM layer at E11.5 (B, arrowhead), and
ype lungs shows expression throughout the developing lung mesenchyme surrounding
rβ expression is reduced at E11.5 (F) and E14.5 (H) in the mesenchyme underlying the
imitive blood vessels (H, v). Q-PCR demonstrates a signiﬁcant reduction in SM22α and
.02, ** pb0.001 (Student's t test). N=5 lung buds. Airways denoted by (*) symbol on
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Fig. 4. Assessment of endothelial differentiation in Wnt2−/− null lungs. Q-PCR indicates no signiﬁcant change in expression levels of the endothelial marker gene Pecam in E12.5
Wnt2−/− null lung buds compared to control wild type lung buds (A). Assessment of the endothelial marker gene Flk1 reveals the expression level in Wnt2−/− null lung buds is
signiﬁcantly reduced to approximately 85% when normalized to control lung buds (B). Analysis of the Vegf family members indicates no signiﬁcant change in expression levels
between E12.5 control and Wnt2−/− null lung buds for Vegf-A (C) and Vegf-D (D). However, Vegf-C is reduced by approximately 30% in Wnt2−/− null lungs when normalized to
control lungs (E). Expression of Vegfr3, a receptor for Vegf-C in the lung, is not signiﬁcantly reduced inWnt2−/− null lungs (F). Analysis of the lymphatic marker gene Lyve1 shows no
change in expression level between control and Wnt2−/− null lung buds (G). *, pb0.05 (Student's t test). N=5 lung buds. N.S.=not statistically signiﬁcant.
546 A.M. Goss et al. / Developmental Biology 356 (2011) 541–5523 and is critical for early development of the lymphatic vasculature
(Veikkola et al., 2001). Expression of Vegfr-3 was also analyzed in
E12.5 control andWnt2−/− null lung buds and Q-PCR showed a slight
but not signiﬁcant reduction in Vegfr-3 expression in the absence of
Wnt2 function (Fig. 4F). Expression of Lyve-1, another marker oflymphatic endothelium (Banerji et al., 1999), was unchanged in
Wnt2−/− null lungs at E12.5 (Fig. 4G). Together, these data indicate
that the loss of Wnt2 signaling in the embryonic lung does not
appreciably effect expression of most early endothelial marker genes
with the exception of minor decreases in Flk-1 and Vegf-C expression.
547A.M. Goss et al. / Developmental Biology 356 (2011) 541–5522.6. Expression of signaling pathways important for smooth muscle
development in Wnt2−/− null lungs
Several signaling pathways are critical for smooth muscle
development in the mouse lung including the Shh, Bmp, Wnt7b,
and Fgf10 signaling pathways (reviewed in (Morrisey and Hogan,
2010). Wnt2 is expressed in the primitive mesenchyme that is
condensing around the tracheal bifurcation and presumptive lung bud
(Goss et al., 2009), and Wnt2 signaling may regulate smooth muscle
development up or downstream of any of these pathways. In situ
hybridization and Q-PCR on wild type and Wnt2−/− null mutant
embryos showed that Wnt7b expression is reduced in Wnt2−/− null
mutant foreguts (Fig. 5A–C). Fgf10 is a ligand that is expressed in the
developing lung mesenchyme and mediates lung bud outgrowth and
ASM development and has been shown to be a direct downstream
target of canonicalWnt/β-catenin signaling (Cohen et al., 2007). Fgf10
expression in the mesenchyme of Wnt2−/− null mutant lungs is
reduced (Fig. 5D–F). Shh and Bmp4 are well-established epithelial–
mesenchymal regulators of smooth muscle development in the lungW
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Fig. 5. Evaluation of signaling factors important for smooth muscle development in Wnt2−
embryos (B, E, H, K) to detect expression of Wnt7b (A and B), Fgf10 (D and E), Shh (G an
expression of Wnt7b (C), Fgf10 (F), Shh (I), and Bmp4 (L) in wild type and Wnt2−/− null
N.S.=not statistically signiﬁcant. Lung bud circumscribed with dashed line in panels D,
bars=100 μm (A–K).during branching morphogenesis (Bellusci et al., 1997a, 1997b;
Weaver et al., 2000, 1999). In Shh−/− null mutant lungs there is a
dramatic loss of smooth muscle development (Bellusci et al., 1997a;
Pepicelli et al., 1998), and activation of Bmp4 signaling been shown to
be downstream of Fgf10 signaling (Mailleux et al., 2005). In situ
hybridization and Q-PCR show that Shh expression is not changed in
Wnt2-/− null mutant lungs (Fig. 5G–I). Expression of Bmp4 is also
unaltered in Wnt2−/− lungs (Fig. 5J–L). Taken together, these data
suggests that Wnt2 signaling acts upstream of Wnt7b and Fgf10
expression, but not Shh or Bmp4, in the primitive lung mesenchyme.
2.7. Wnt2 signaling is sufﬁcient to promote smooth muscle gene
expression and development in the lung
Although Wnt2−/− mutants display severe defects in ASM
development, it is unclear whether Wnt2 signaling is sufﬁcient to
promote smooth muscle differentiation and development in the lung
mesenchyme. To test whether Wnt2 signaling was sufﬁcient to
activate the smooth muscle differentiation program in mesenchymal/-
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548 A.M. Goss et al. / Developmental Biology 356 (2011) 541–552cells, we treated the mesenchymal cell line 10T1/2, a cell line known
to differentiate into smooth muscle cells under certain culture
conditions (Darland and D'Amore, 2001; Lockman et al., 2007;
Wang et al., 2007b), with recombinant Wnt2 (rWnt2). Culturing
10T1/2 cells in the presence of rWnt2 for 48 hours led to increased
expression of several smooth muscle related genes including SM22α,
SMA, Pdgfrα, and Pdgfrβ, as assessed by Q-PCR (Fig. 6A). Expression of
the canonical Wnt target gene Axin2 was also signiﬁcantly upregu-
lated in the presence of rWnt2, indicating activation of Wnt/β-catenin
signaling in 10T1/2 cells by this recombinant ligand (Fig. 6A).
To further investigate the effects of rWnt2 on smooth muscle
development, E11.5wild type lung budsweredissected and cultured for
48 h with either control PBS or rWnt2 in a lung explant assay. Explants
were collected and examined for changes in smooth muscle develop-
ment by histology and Q-PCR. In lung bud explants cultured in the
presence of rWnt2, SM22α,myocardin,MRTFB, Fgf10, Pdgfrβ, and Pdgfrα
expression were all signiﬁcantly increased (Fig. 6B). This increase in
smoothmuscle gene expressionwas accompanied by increased smooth
muscle cell development around the developing airways in the rWnt2C
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Wnt7b expression were also examined by Q-PCR to determinewhether
rWnt2 activated expression of these pro-myogenic epithelial expressed
factors. Interestingly in the presence of rWnt2, expression ofWnt7bwas
signiﬁcantly upregulated whereas Bmp4 expression was not signiﬁ-
cantly increased when compared to control wild type untreated lung
bud explants (Fig. 6E). This data in conjunction with the decreased
Wnt7b expression in Wnt2−/− null mutants suggests that Wnt2
signaling coordinates smooth muscle development in part through
activated Wnt7b signaling.
The whole lung bud explant assay does not permit the assessment
of Wnt2 autocrine signaling on activation of smooth muscle gene
expression. To assess the role of autocrine Wnt2 signaling in the lung
mesenchyme in the absence of endoderm, primary cultures of isolated
E11.5 wild type lung mesenchyme were cultured in the absence or
presence of rWnt2 for 48 h. In the presence of rWnt2, the expression
of several smooth muscle genes were signiﬁcantly upregulated
including myocardin, MRTFB, Fgf10, SM22α, Pdgfrα, and SMA
(Fig. 6F). Surprisingly Fgf10 expression was increased 5-fold in theB
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via autocrine Wnt2 signaling in the primitive lung mesenchyme.
Although activation of smooth muscle gene expression occurred in
primary lung mesenchyme cultures treated with rWnt2, the overall
magnitude was less compared to whole lung bud explant cultures.
These data suggest that Wnt2 mediated paracrine signaling also
contributes to smooth muscle gene expression and development in
the lung.
2.8. Fgf10 signaling does not activate Wnt2 expression in the lung
Genetic models have shown that Fgf10 signaling is necessary for
ASM development in the lung (Mailleux et al., 2005; Ramasamy et al.,
2007). Our data show that loss of Wnt2 expression leads to decreased
Fgf10 expression (Fig. 5D–F). However it is unclear whether Wnt2
simply acts upstream of Fgf10 signaling to promote smooth muscle
development or whether Fgf10 also cooperates to increase Wnt2SM
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modulates Wnt2 expression, E11.5 wild type lung bud explants were
treated with either PBS or recombinant Fgf10 (rFgf10) and expression
of Wnt2 was analyzed by Q-PCR. Wnt2 gene expression levels were
unaffected by exogenous rFgf10 in wild type lung bud explants,
suggesting that Fgf10 signaling neither activates nor inhibits Wnt2
expression (Fig. 7A). Treatment of lung bud explants with rFgf10 did
result in a signiﬁcant upregulation of several smooth muscle marker
genes including SM22α, SMA, and Pdgfrα but not myocardin or Mrtf-B
(Fig. 7A). This upregulation in smooth muscle gene expression was
conﬁrmed by SM22α immunostaining showing increased ASM
development in rFgf10 treated wild type explants (Fig. 7B and C).
Previous reports examining Fgf10 hypomorphic models suggested
that Fgf10 regulates smooth muscle development through epithelial
intermediates including Bmp4 (Mailleux et al., 2005). However, we
did not observe a signiﬁcant increase in Bmp4 and Wnt7b expression
in the presence of rFgf10 (Supplemental Fig. 3).rFGF10
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The data thus far suggests that Wnt2 signaling mediates ASM
development in part, through activation of Fgf10 signaling. To
determine whether exogenous Fgf10 could rescue the loss of smooth
muscle development in Wnt2−/− null mutant lungs, E11.5 lung buds
were dissected from Wnt2+/− heterozygous mutant crosses for lung
explant rescue assays with rFgf10. Lung bud explants were individ-
ually cultured in the presence of either PBS or rFgf10 for 48 h, and
subsequently harvested for histological sectioning and Q-PCR. rFgf10
treatment of Wnt2−/− null lung bud explants resulted in increased
levels of SM22α, Pdgfrβ, and SMA (Fig. 7D). Expression of myocardin,
Mrtf-B, and Pdgfrα was not statistically changed (Fig. 7D). However,
there was a less than signiﬁcant rescue in Wnt7b expression with
addition of Fgf10 (Fig. 7D). Immunostaining for SM22α expression
also showed increased smooth muscle development in rFgf10 treated
Wnt2−/− null lung bud explants supporting the Q-PCR ﬁndings
(Fig. 7E−G). Overall, these data suggest that rFgf10 acts downstream
of Wnt2 to promote the expansion and differentiation of smooth
muscle cells in the lung that have already initiated expression of
myocardin and Mrtf-B (Fig. 8).
3. Discussion
Our data indicate thatWnt2 signaling is necessary and sufﬁcient to
promote the differentiation of ASM from the multipotent lung
mesenchyme through direct or indirect activation of a myogenic
regulatory network includingmyocardin andMrtf-B. These data show
that Wnt2 signaling activates Fgf10 signaling in the mesenchyme,
which further drives proliferation and smooth muscle differentiation
into mature ASM. Our results also suggest that Wnt2 signaling
activates Wnt7b signaling in the adjacent epithelium, which is known
to signal in a paracrine manner to the sup-epithelial mesenchyme to
promote smooth muscle differentiation.
Smooth muscle development in the lung is poorly understood in
part because the origins of the various smooth muscle lineages are
still unclear and the pathways regulating proliferation, migration,
and differentiation of primitive smooth muscle cells are complex
and unresolved. Recent genetic evidence demonstrates that Wnt/β-
catenin signaling lies upstream of signals governing smooth muscle
development in themouse lung. Loss of the canonical ligandWnt7b in
the embryonic lung epithelium leads to severe VSM defects,
demonstrating a critical role for paracrine Wnt/β-catenin signaling
between the developing epithelium and mesenchyme (Cohen et al.,
2009; Shu et al., 2002). Additional studies demonstrate that genetic
deletion of β-catenin in the primitive lung mesenchyme also disruptsWnt2
Airway 
epithelium
Wnt7b
Fig. 8.Model of Wnt2 signaling in ASM development. Wnt2 signaling in the primitive lung m
multipotent mesenchyme into early-stage smooth muscle cells in part, by activating a myog
of the pro-myogenic ligand Wnt7b in the adjacent epithelium. Wnt2 signaling also activates
smooth muscle cells into mature smooth muscle cells expressing ASM markers including S
muscle program by Fgf10 is direct or indirect through intermediates (i.e. factor X) is uncleaASM development (De Langhe et al., 2008), implicating a potential
function for other canonical Wnt ligands expressed in the lung for
proper ASM development. In this study, we identify Wnt2 as a critical
Wnt ligand required in the lung mesenchyme to mediate ASM
development. We show that Wnt2 is required for BAT-GAL activity in
ASM indicating that it acts through the β-catenin dependent canonical
pathway to regulate ASM development.
While defects in ASM are observedWnt2−/− null mutants, the VSM
appears grossly normal. Wnt7b signaling from the lung epithelium has
been shown to regulate VSMdevelopment (Cohenet al., 2009; Shu et al.,
2002), and analysis of Wnt2−/− null mutant lungs demonstrates that
Wnt7b is expressed at about 50% of normal levels in Wnt2−/− null
mutants. Additionally, Wnt2 expression is reduced in Wnt7b−/− null
lungs (unpublished observations), suggesting there is signaling inter-
play between epithelial andmesenchymal expressedWnt ligands in the
lung. IfWnt2 signaling is important for VSMdevelopment, the potential
effects from loss of Wnt2 signaling may be compensated by the
continued expression ofWnt7borWnt2b,which is also expressed in the
lungmesenchyme and could function redundantly withWnt2 signaling
in VSM development (Goss et al., 2009). The distinct molecular
pathways that regulate VSM versus ASM development in the lung are
poorly understood. Moreover, it is unclear whether ASM and VSM have
a common or distinct developmental origins. Disruption of other
pathways including Shh result in defects in both ASM and VSM (Miller
et al., 2004). Thus, additional fate-mapping as well as developmental
studies will be required to determine the similarities and differences in
VSM and ASM origins and cellular phenotypes.
A recent study describing conditional mutants in β-catenin
signaling in the developing lung mesenchyme suggested a role for
Wnt/β-catenin in the differentiation of the endothelial lineage (De
Langhe et al., 2008).Wnt2−/− null embryoid bodies are also unable to
effectively differentiate into endothelial cells (Wang et al., 2007a).
Our data suggests that eitherWnt2 is not required for lung endothelial
development or that it acts redundantly with other Wnt ligands to
regulate endothelial development in the lung.
Wnt2 is expressed during the earliest stages of lung morphogen-
esis suggesting the perinatal ASM deﬁciency inWnt2−/− null mutants
could be the result of an early defect in the development of smooth
muscle cells in the distal mesenchyme. Analysis of Wnt2−/− null
mutants during the early stages of myogenesis indicated reduced
expression of the genes regulating the earliest aspects of smooth
muscle cell differentiation from the primitive mesenchyme including
myocardin,Mrtf-B, and Pdgfrβ. These data indicate thatWnt2 signaling
regulates the development of the multipotent mesenchymal into
immature smooth muscle cells in the mouse lung.
AWnt-Fgf regulatory network is thought to govern development of
the lungmesenchyme (Yin et al., 2008), andmice carryinghypomorphicFgf10
ASM
factor X
esenchyme promotes the proliferation and differentiation of the Pdgfrα/β-expressing
enic transcriptional network including myocardin and Mrtf-B and activating expression
Fgf10 signaling, which further promotes ampliﬁcation and differentiation of immature
M22α, SMA, and Pdgfrα. Whether the ampliﬁcation and differentiation of the smooth
r.
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ASM deﬁciencies (De Langhe et al., 2006; Ramasamy et al., 2007). In
Wnt2−/− null mutant lungs, both Fgf10 expression and Fgfr2 expression
are reduced, implicating a Wnt2-Fgf10 signaling network in the
coordination of ASM development. We show that Fgf10 signaling
promotes ASM development through upregulation of several mature
smoothmusclemarkers but not the early smoothmuscle differentiation
factorsmyocardin orMrtf-B. Theseﬁndings suggest that Fgf10 signaling
mediates the expansion and differentiation of immature smoothmuscle
cell already committed to the ASM lineage.
In summary, these studies demonstrate that Wnt2 signaling is
necessary for ASM development in the mouse lung. Wnt2 expression
during early lung morphogenesis is required for activation of the
smooth muscle gene expression program including myocardin, Mrtf-
B, and Fgf10. Exogenous Fgf10 can partly rescue the loss of Wnt2 by
promoting differentiation of cells already committed to the ASM
lineage. Thus, these results deﬁne a Wnt2-Fgf10 signaling axis
governing early ASM development in the lung.
4. Materials and methods
4.1. Mice
Generation and genotyping information on the Wnt2−/− mutant
mice has been described (Goss et al., 2009). Genotyping of the BAT-
GALmice has been described (Maretto et al., 2003). The University of
Pennsylvania Institutional Animal Care and Use Committee approved
all animal protocols.
4.2. Histology
Embryos were ﬁxed in 4% paraformaldehyde for 24 h, dehydrated
in a series of ethanol washes, and then embedded in parafﬁn for tissue
sectioning. Dissected embryonic lung buds and foreguts were ﬁxed in
4% paraformaldehyde overnight, dehydrated in a series of methanol
washes and blocked a 10% normal goat serum/PBS solution before
wholemount immunostaining. Radioactive in situ hybridization and
immunohistochemistry were performed as previously described (Shu
et al., 2001). Tissue sections were stained with the following
antibodies and dilutions: anti-Axin2 (Abcam; 1:100), anti-Pdgfrβ
(Cell Signaling Technology Inc.; 1:50), anti-PECAM-1 (PharMingen;
1:500), and anti-SM22α (Abcam; 1:500). β-galactosidase histochem-
ical staining of embryoswas performed as previously described by our
laboratory (Shu et al., 2002).
4.3. Quantitative RT-PCR
Total RNA was isolated from lung tissue at the indicated time
points using Trizol reagent, reverse transcribed using SuperScript First
Strand Synthesis System (Invitrogen), and used in quantitative real
time PCR (Q-PCR) analysis using the oligonucleotides listed in
Supplemental Table 1. RNA was isolated from at least 5 lung bud
tissue samples corresponding to each genotype.
4.4. Lung explant and primary mesenchyme cultures
Lung buds were dissected from E11.5 embryos and cultured in
BGjb media (Invitrogen) supplemented with 0.1 mg/ml ascorbic acid
for 48 h as previously described (Zhang et al., 2008). Explants were
cultured on a 0.4 μm membrane ﬁlter (BD Falcon). For mesenchymal
cultures, whole lung buds were dissected at E11.5 and subjected to
collagenase digestion to give rise to single cells and mesenchymal
cells were isolated via differential adhesion. For rescue experiments,
embryos were collected from wild type females or generated from
Wnt2+/− heterozygous mutant crosses. Exogenous recombinant
human Wnt2 protein (Novus Biologicals) was added to the lungexplant media at a concentration of 0.15 μg/ml. Exogenous recombi-
nant human Fgf10 (R & D Systems, Inc.) was added to the lung explant
media at a concentration of 0.2 μg/ml. At least 8 explants were used
for each experimental condition and treatment.
4.5. Cell culture
10T1/2 cells were cultured in Eagle's Basal medium with Earle's
BSS, 2 mML-glutamine, 1.5 g/L sodium bicarbonate, and 10% heat-
inactivated fetal bovine serum as suggested by ATCC. Recombinant
human Wnt2 protein was added to the 10T1/2 media at a concentra-
tion of 0.15 μg/ml, and cultured for 48 h before harvesting for Q-PCR
analysis.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.ydbio.2011.06.011.
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